Improved anti-tumor efficiency against prostate cancer by docetaxel-loaded PEG-PCL micelles

Abstract

This study primarily focused on the systematic assessment of both in vitro and in vivo anti-tumor effects of docetaxel-loaded polyethylene glycol (PEG)₂₀₀₀-polycaprolactone (PCL)₂₆₀₀ micelles on hormone-refractory prostate cancer (HRPC). By using solvent evaporation method, PEG-PCL was chosen to prepare doxetaxel (DTX)-loaded mPEG-PCL micelles (DTX-PMs), with the purpose of eliminating side effects of the commercial formulation (Tween 80) and prolonging the blood circulation time. The prepared DTX-PMs had an average particle size of 25.19±2.36 nm, a zeta potential of 0.64±0.15 mV, a polydispersity index of 0.56±0.03, a drug loading of (8.72±1.05)%, and an encapsulation efficiency of (98.1±8.4)%. In vitro cytotoxicity studies indicated that DTX-PMs could effectively kill LNCap-C4-2B cells and show a dose- and time-dependent efficacy. The hemolysis test showed that DTX-PMs had less hemocytolysis than the commercial product of Duopafei®. A sustained in vitro release behavior and prolonged circulation time in blood vessels were observed in the DTX-PMs. Furthermore, when compared with Duopafei®, the DTX-PMs dramatically reduced the prostate specific antigen (PSA) level and tumor growth of prostate tumor-bearing nude mice in vivo. In conclusion, the DTX-PMs can lower systemic side effects, improve anti-tumor activity with prolonged blood circulation time, and will bring an alternative to patients with HRPC.

Keywords

hormone-refractory prostate cancer / LNCap-C4-2B / docetaxel / polymeric micelles

References

[1] DamberJE, AusG. Prostate cancer. Lancet, 2008, 371(9625): 1710-1721

[2] CrawfordED, EisenbergerMA, McLeodDG, et al.. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med, 1989, 321(7): 419-424

[3] CheungFY, LeungKC, NganRK. Docetaxel chemotherapy for Chinese patients with castrate-resistant prostate cancer. Hong Kong Med J, 2013, 19(3): 237-241

[4] PetrylakDP, TangenCM, HussainMH, et al.. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med, 2004, 351(15): 1513-1520

[5] FeldmanBJ, FeldmanD. The development of androgen-independent prostate cancer. Nat Rev Cancer, 2001, 1(1): 34-45

[6] PrapotnichD, FizaziK, EscudierB, et al.. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol, 2003, 43(3): 233-239

[7] TannockIF, de WitR, BerryWR, et al.. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med, 2004, 351(15): 1502-1512

[8] SingerEA, SrinivasanR. Intravenous therapies for castration-resistant prostate cancer: toxicities and adverse events. Urol Oncol, 2012, 30(4Suppl): S15-19

[9] YaredJA, TkaczukKH. Update on taxane development: new analogs and new formulations. Drug Des Devel Ther, 2012, 6: 371-384

[10] LiuQ, LiR, ZhuZ, et al.. Enhanced antitumor efficacy, biodistribution and penetration of docetaxel-loaded biodegradable nanoparticles. Int J Pharm, 2012, 430(1–2): 350-358

[11] DuncanR, RingsdorfH, Satchi-FainaroR. Polymer therapeutics—polymers as drugs, drug and protein conjugates and gene delivery systems: past, present and future opportunities. J Drug Target, 2006, 14(6): 337-341

[12] MatsumuraY. Preclinical and clinical studies of anticancer drug-incorporated polymeric micelles. J Drug Target, 2007, 15(7–8): 507-517

[13] WeissigV, WhitemanKR, TorchilinVP. Accumulation of protein-loaded long-circulating micelles and liposomes in subcutaneous Lewis lung carcinoma in mice. Pharm Res, 1998, 15(10): 1552-1556

[14] LukyanovAN, GaoZ, MazzolaL, et al.. Polyethylene glycol-diacyllipid micelles demonstrate increased acculumation in subcutaneous tumors in mice. Pharm Res, 2002, 19(10): 1424-1429

[15] MaedaH, WuJ, SawaT, et al.. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release, 2000, 65(1–2): 271-284

[16] ZambauxMF, BonneauxF, GrefR, et al.. MPEO-PLA nanoparticles: effect of MPEO content on some of their surface properties. J Biomed Mater Res, 1999, 44(1): 109-115

[17] IyerAK, GreishK, SekiT, et al.. Polymeric micelles of zinc protoporphyrin for tumor targeted delivery based on EPR effect and singlet oxygen generation. J Drug target, 2007, 15(7–8): 496-506

[18] FangJ, NakamuraH, MaedaH. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev, 2011, 63(3): 136-151

[19] LuoY, LingY, GuoW, et al.. Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells. J Control Release, 2010, 147(2): 278-288

[20] CabralH, MatsumotoY, MizunoK, et al.. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol, 2011, 6(12): 815-823

[21] TangN, DuG, WangN, et al.. Improving penetration in tumors with nano assemblies of phospholipids and doxorubicin. J Natl Cancer Inst, 2007, 99(13): 1004-1015

[22] LukyanovAN, GaoZ, TorchilinVP. Micelles from polyethylene glycol/phosphatidylethanolamine conjugates for tumor drug delivery. J Control Release, 2003, 91(1–2): 97-102

[23] ImmordinoML, BrusaP, ArpiccoS, et al.. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J Control Release, 2003, 91(3): 417-429

[24] ZhengD, LiX, XuH, et al.. Study on docetaxel-loaded nanoparticles with high antitumor efficacy against malignant melanoma. Acta Biochim Biophys Sin (Shanghai), 2009, 41(7): 578-587

[25] YuanZ, ChenD, ZhangS, et al.. Preparation, characterization and evaluation of docetaxel-loaded, folate-conjugated PEG-liposomes. Yakugaku Zasshi, 2010, 130(10): 1353-1359

[26] LiuSQ, WiradharmaN, GaoSJ, et al.. Bio-functional micelles self-assembled from a folate-conjugated block copolymer for targeted intracellular delivery of anticancer drugs. Biomaterials, 2007, 28(7): 1423-1433

[27] LiX, LiR, QianX, et al.. Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate. Eur J Pharm Biopharm, 2008, 70(3): 726-734

[28] JenkinsDE, OeiY, HornigYS, et al.. Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. Clin Exp Metastasis, 2003, 20(8): 733-744

[29] DanhierF, LecouturierN, VromanB, et al.. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Release, 2009, 133(1): 11-17

[30] GaoZ, LukyanovAN, SinghalA, et al.. Diacylpolymer micelles as nanocarriers for poorly soluble anticancer drugs. Nano Lett, 2002, 2(9): 979-982

[31] ChenW, GuB, WangH, et al.. Development and evaluation of novel itraconazole-loaded intravenous nanoparticles. Int J Pharm, 2008, 362(1–2): 133-140

[32] KimD, GaoZG, LeeES, et al.. In vivo evaluation of doxorubicin-loaded polymeric micelles targeting folate receptors and early endosomal pH in drug-resistant ovarian cancer. Mol Pharm, 2009, 6(5): 1353-1362

[33] GaoZG, FainHD, RapoportN. Controlled and targeted tumor chemotherapy by micellar-encapsulated drug and ultrasound. J Control Release, 2005, 102(1): 203-222

[34] MasterAM, RodriguezME, KenneyME, et al.. Delivery of the photosensitizer Pc 4 in PEG-PCL micelles for in vitro PDT studies. J Pharm Sci, 2010, 99(5): 2386-2398

[35] ZhangL, YangM, WangQ, et al.. 10-Hydroxy camptothecin loaded nanoparticles: preparation and antitumor activity in mice. J Control Release, 2007, 119(2): 153-162

[36] KimTY, KimDW, ChungJY, et al.. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res, 2004, 10(11): 3708-3716

[37] LeeSW, YunMH, JeongSW, et al.. Development of docetaxel-loaded intravenous formulation, Nanoxel-PM using polymer-based delivery system. J Control Release, 2011, 155(2): 262-271

[38] ChenW, ZhanC, GuB, et al.. Targeted brain delivery of itraconazole via RVG29 anchored nanoparticles. J Drug target, 2011, 19(3): 228-234

[39] Van VlerkenLE, VyasTK, AmijiMM. Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm Res, 2007, 24(8): 1405-1414

[40] MuL, TeoMM, NingHZ, et al.. Novel powder formulations for controlled delivery of poorly soluble anticancer drug: application and investigation of TPGS and PEG in spray-dried particulate system. J Control Release, 2005, 103(3): 565-575

[41] GongC, XieY, WuQ, et al.. Improving anti-tumor activity with polymeric micelles entrapping paclitaxel in pulmonary carcinoma. Nanoscale, 2012, 4(19): 6004-6017

[42] XiaoL, XiongX, SunX, et al.. Role of cellular uptake in the reversal of multidrug resistance by PEG-b-PLA polymeric micelles. Biomaterials, 2011, 32(22): 5148-5157

[43] ZhangL, HuY, JiangX, et al.. Camptothecin derivative-loaded oly (caprolactone-co-lactide)-b-PEG-b-poly (caprolactone-co-lactide) nanoparticles and their biodistribution in mice. J Control Release, 2004, 96(1): 135-148

[44] Le GarrecD, GoriS, LuoL, et al.. Poly(N-vinylpyrrolidone)-block-poly (D,L-lactide) as a new polymeric solubilizer for hydrophobic anticancer drugs: in vitro and in vivo evaluation. J Control Release, 2004, 99(1): 83-101

[45] MoghimiSM, HunterAC, MurrayJC. Long-circulating and target-specific nanoparticles: theory to practice. Pharm Rev, 2001, 53(2): 283-318

[46] YokoyamaM. Polymeric micelles as a new drug carrier system and their required considerations for clinical trials. Expert Opin Drug Deliv, 2010, 7(2): 145-158

[47] ManjunathK, VenkateswarluV. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release, 2005, 107(2): 215-228

[48] WangF, ZhangD, ZhangQ, et al.. Tissue distribution and pharmacokinetics evaluation of DOMC-FA micelles for intravenous delivery of PTX. J Drug Target, 2013, 21(2): 137-145

[49] JainRK. Transport of molecules in the tumor interstitium: a review. Cancer Res, 1987, 47(12): 3039-3051

[50] HobbsSK, MonskyWL, YuanF, et al.. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A, 1998, 95(8): 4607-4612

[51] YuanF, DellianM, FukumuraD, et al.. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res, 1995, 55(17): 3752-3756

[52] CatalonaWJ, RichieJP, AhmannFR, et al.. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol, 1994, 151(5): 1283-1290

[53] HerschmanJD, SmithDS, CatalonaWJ. Effect of ejaculation on serum total and free prostate-specific antigen concentrations. Urology, 1997, 50(2): 239-243

[54] NadlerRB, HumphreyPA, SmithDS, et al.. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol, 1995, 154(2Pt1): 407-413